will be administered as a daily subcutaneous injection. G-CSF 
will be supplied by the Division of Cancer Treatment, NCI. 
9.0 Drug Toxicity 
9.1 Etoposides causes myelosuppression, nausea, vomiting, 
alopecia, mucositis, hypotension with rapid infusion, 
hypersensitivity reactions, local phlebitis, peripheral 
neuropathy, cholestasis and cardiac arrhythmias. 
9.2 Ifosfamide may cause hemorrhagic cystitis which is prevented 
by MESNA. At doses in the ICE regimen, it may cause renal 
damage and hepatitis. A neurologic syndrome characterized by 
somnolence and confusion occurs in approximately 25% of the 
patients. Myelosuppression, nausea and vomiting and transient 
renal tubular acidosis are uniform side effects. Hyponatremia 
(SIADH) has occurred infrequently. 
9.3 CBDCA causes myelosuppression, nausea and vomiting, 
ototoxicity, nephrotoxicity, and hepatitis. Less frequently, it 
causes allergic reactions, dizziness, blurred vision, 
hypercalcemia, fever, interstitial pneumonitis, hemolysis, 
hemolytic uremic syndrome and hyponatremia. 
9.4 MESNA causes diarrhea, nausea and vomiting. 
9.5 Vinblastine causes nausea and vomiting, alopecia, mucositis, 
constipation, bone marrow suppression, liver dysfunction and 
neuropathy. In addition, vinblastine can cause tissue damage if 
extravasation occurs. 
9.6 G-CSF toxicity consists mainly of bone pain which can be 
severe. Other adverse reactions include constitutional 
symptoms (nausea, fatigue, headache and myalgias), lethargy, 
muscle cramps, back/leg pain and exacerbations of pre- 
existing inflammatory conditions (e.g., psoriasis, 
vasculitides). Fever is uncommon but has been reported. A 
reversible elevation in leukocyte alkaline phosphatase, uric 
Recombinant DNA Research, Volume 16 
[115] 
